224 related articles for article (PubMed ID: 9057699)
1. Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes.
Ali N; Afrin F
J Parasitol; 1997 Feb; 83(1):70-5. PubMed ID: 9057699
[TBL] [Abstract][Full Text] [Related]
2. Induction of partial protection against Leishmania donovani by promastigote antigens in negatively charged liposomes.
Afrin F; Anam K; Ali N
J Parasitol; 2000 Aug; 86(4):730-5. PubMed ID: 10958448
[TBL] [Abstract][Full Text] [Related]
3. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis.
Sharma SK; Dube A; Nadeem A; Khan S; Saleem I; Garg R; Mohammad O
Vaccine; 2006 Mar; 24(11):1800-10. PubMed ID: 16310900
[TBL] [Abstract][Full Text] [Related]
4. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
Mazumdar T; Anam K; Ali N
Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
[TBL] [Abstract][Full Text] [Related]
5. Comparison of liposome based antigen delivery systems for protection against Leishmania donovani.
Bhowmick S; Mazumdar T; Sinha R; Ali N
J Control Release; 2010 Jan; 141(2):199-207. PubMed ID: 19818373
[TBL] [Abstract][Full Text] [Related]
6. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
Nagill R; Kaur S
Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
[TBL] [Abstract][Full Text] [Related]
7. Isotype profiles of Leishmania donovani-infected BALB/c mice: preferential stimulation of IgG2a/b by liposome-associated promastigote antigens.
Afrin F; Ali N
J Parasitol; 1998 Aug; 84(4):743-8. PubMed ID: 9714204
[TBL] [Abstract][Full Text] [Related]
8. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis.
Rachamim N; Jaffe CL
J Immunol; 1993 Mar; 150(6):2322-31. PubMed ID: 8450215
[TBL] [Abstract][Full Text] [Related]
9. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.
Bhowmick S; Ravindran R; Ali N
Vaccine; 2007 Aug; 25(35):6544-56. PubMed ID: 17655984
[TBL] [Abstract][Full Text] [Related]
10. Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis.
Nagill R; Mahajan R; Sharma M; Kaur S
Parasitol Int; 2009 Dec; 58(4):359-66. PubMed ID: 19638322
[TBL] [Abstract][Full Text] [Related]
11. Influence of phospholipid composition on the adjuvanticity and protective efficacy of liposome-encapsulated Leishmania donovani antigens.
Mazumdar T; Anam K; Ali N
J Parasitol; 2005 Apr; 91(2):269-74. PubMed ID: 15986599
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
[TBL] [Abstract][Full Text] [Related]
13. Non-coding pDNA bearing immunostimulatory sequences co-entrapped with leishmanial antigens in cationic liposomes elicits almost complete protection against experimental visceral leishmaniasis in BALB/c mice.
Mazumder S; Ravindran R; Banerjee A; Ali N
Vaccine; 2007 Dec; 25(52):8771-81. PubMed ID: 18031874
[TBL] [Abstract][Full Text] [Related]
14. Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes.
Afrin F; Ali N
Infect Immun; 1997 Jun; 65(6):2371-7. PubMed ID: 9169776
[TBL] [Abstract][Full Text] [Related]
15. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.
Oliveira-Freitas E; Casas CP; Borja-Cabrera GP; Santos FN; Nico D; Souza LO; Tinoco LW; da Silva BP; Palatnik M; Parente JP; Palatnik-de-Sousa CB
Vaccine; 2006 May; 24(18):3909-20. PubMed ID: 16556475
[TBL] [Abstract][Full Text] [Related]
16. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization.
Kahl LP; Scott CA; Lelchuk R; Gregoriadis G; Liew FY
J Immunol; 1989 Jun; 142(12):4441-9. PubMed ID: 2786033
[TBL] [Abstract][Full Text] [Related]
17. Serodiagnostic and immunoprophylactic potential of a 78kDa protein of Leishmania donovani of Indian origin.
Mukherjee M; Bhattacharyya A; Duttagupta S
Med Sci Monit; 2002 Apr; 8(4):BR117-22. PubMed ID: 11951057
[TBL] [Abstract][Full Text] [Related]
18. Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection.
Daifalla NS; Bayih AG; Gedamu L
Exp Parasitol; 2012 Jul; 131(3):317-24. PubMed ID: 22580023
[TBL] [Abstract][Full Text] [Related]
19. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
Melby PC; Yang J; Zhao W; Perez LE; Cheng J
Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
Ravindran R; Maji M; Ali N
Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
